Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on November 16, 2022. The filing discloses the entry into a material definitive agreement and the issuance of unregistered equity securities involving the company's interim Executive Chairman.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to a specific capital transaction:
- Transaction Amount: $1,750 in cash received.
- Security Issued: One (1) share of Series D Preferred Stock.
- Redemption Value: $1,750 cash upon redemption.
Material Changes
The primary material change is the issuance of Series D Preferred Stock to Robert J. Bitterman, the interim Executive Chairman. This issuance alters the company's capital structure and voting rights specifically regarding reverse stock split proposals. The transaction closed on November 16, 2022.
Outlook, Risks, and Unusual Items
Unusual Item (Voting Rights): The Series D Preferred Stock carries 17,500,000 votes per share. These votes are exercisable exclusively on proposals to amend the Certificate of Incorporation to effect a reverse stock split of the Common Stock. The Preferred Stock votes automatically in the same proportion as the Common Stock on such proposals without action by the holder.
Liquidity and Dividends: The Preferred Stock has no dividend rights and no rights to asset distributions upon liquidation or bankruptcy. It is redeemable at the Board's discretion or automatically upon the approval of a reverse stock split.
Regulatory Status: The sale was exempt from registration under Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the specific voting mechanics of the Series D Preferred Stock regarding reverse stock split proposals.
- Confirm the redemption terms and the Board's discretion to redeem the stock.
- Review the full Subscription Agreement (Exhibit 10.1) for representations and warranties.
- Check subsequent filings for any actual redemption of the Preferred Stock or approval of a reverse stock split.